Driven by a 14.9% CAGR, the global prebiotic market is undergoing a paradigm shift from basic fiber to precision biotech molecules (HMOs, SynBio-derived XOS). While this suggests massive commercial upside, countless brands encounter severe structural vulnerabilities in the "Valley of Death" due to post-launch sensory degradation.
The core issue is a fundamental mistranslation between biotech R&D and the factory floor. This report merges global supply chain tectonics with molecular physics, establishing why Strategic Vendor Architecture (SVA) is the essential bridge between high-end biotechnology and commercial scale-up.